UTMB’s Thomas Geisbert has done animal studies on the Tekmira drug and said there are few companies willing to develop Ebola treatments. There is “little financial incentive,” given the small market potential for a drug that treats a rare disease afflicting developing countries, he said. Geisbert said the drug “works great in monkeys in the lab,” but that is largely because it is given relatively early in the course of infection. “What if you start giving it to people who are almost dead and they die, but it's not the drug's fault? Then you blame the drug.” Geisbert said given the widespread mistrust of doctors in West Africa, which has driven dozens of victims to evade treatment, such an event could jeopardize the drug's prospects. “It’s a very delicate situation,” he said. The Reuters article also appears on Fox News and the Scientific American.